SUMM.L

Summit Therapeutics Plc
Director/PDMR Shareholding
10th February 2020, 14:15
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Director/PDMR Shareholding

Summit Therapeutics plc
(“Summit Therapeutics” or the “Company”)

Notification of Transaction of Persons Discharging Managerial Responsibilities

Oxford, UK, and Cambridge, MA, US, 10 February 2020 - Summit Therapeutics (AIM: SUMM, NASDAQ: SMMT), a leader in antibiotic innovation, announces that it has received notification that on 7 February 2020, Dr Elaine Stracker, a Non-Executive Director of the Company, was assigned for no consideration warrants to acquire a total of 2,099,207 ordinary shares by Maky Zanganeh and Associates, Inc. (“MZA”). The Company has a consultancy agreement with MZA where Dr Stacker serves as General Counsel and Senior Vice President for Corporate Development. 

Following the completion of this transfer, Dr Stracker has the following interest in the Company’s ordinary shares:

  Total number of ordinary shares heldNumber of Outstanding Share Options HeldTotal Number of Outstanding Warrants Held
Elaine StrackerNon-Executive DirectorNil1,000,0002,099,207

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. The person responsible for arranging for the release of this announcement on behalf of the Company is Richard Pye, Vice President, Investor Relations and Corporate Affairs.

About Summit Therapeutics
Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics to treat infections caused by C. difficile, N. gonorrhoeae and Enterobacteriaceae and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc.

For more information, please contact:

Summit  
Glyn Edwards / Richard Pye (UK office)Tel:44 (0)1235 443 951
Michelle Avery (US office) +1 617 225 4455
   
Cairn Financial Advisers LLP (Nominated Adviser)Tel:+44 (0)20 7213 0880
Liam Murray / Tony Rawlinson / Ludovico Lazzaretti  
   



The information set out below is provided in accordance with the requirements of Article 19(3) of the Market Abuse Regulation (EU) No 596/2014.

1Details of the persons discharging managerial responsibilities/person closely associated
a)Name (i)  Dr Elaine Stracker
2Reason for the notification
a)Position / status (i)  Non-Executive Director
b)Initial notification / AmendmentInitial notification
3Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameSummit Therapeutics plc
b)LEI213800NRW8AOMYMTBD89
4Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentOrdinary shares of 1 penny each
  
Identification codeGB00BN40HZ01
b)Nature of the transactionsAssignment of warrants, for no consideration, to acquire ordinary shares of one penny nominal value at a price of 22.1 pence per ordinary share
c)Price(s) and volume(s) Price(s)Volume(s) 
(i) nil

 		 (i)  2,099,207
 
d)Aggregated information

 

- Aggregated volume

 

- Price		 

 

2,099,207 warrants to acquire ordinary shares

 

nil

 
e)Date of the transactions7 February 2020
f)Place of the transactionsOutside a trading venue

-END-

]]>

TwitterFacebookLinkedIn